nicoelnino-shutterstock-com

NicoElNino / Shutterstock.com

13 August 2015Americas

Profit is at the heart of every IPR, says Kyle Bass

Hedge fund manager Kyle Bass has fired a response to a motion filed by biotechnology company Celgene seeking to sanction him over “abusive” patent challenges, stating that profit motive is at the centre of every inter partes review (IPR) filing.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Celgene calls for Kyle Bass sanctions

31 July 2015 Pharmaceutical company Celgene has requested that the US Patent and Trademark Office sanctions hedge fund manager Kyle Bass and his company the Coalition for Affordable Drugs, arguing that the inter partes review petitions he has filed are “abusive” and a “tool to affect the stock prices of public companies”.

USPTO rejects Celgene bid for Bass sanctions

28 September 2015 The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.

More on this story

Celgene calls for Kyle Bass sanctions

31 July 2015 Pharmaceutical company Celgene has requested that the US Patent and Trademark Office sanctions hedge fund manager Kyle Bass and his company the Coalition for Affordable Drugs, arguing that the inter partes review petitions he has filed are “abusive” and a “tool to affect the stock prices of public companies”.

USPTO rejects Celgene bid for Bass sanctions

28 September 2015 The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.

More on this story

Celgene calls for Kyle Bass sanctions

31 July 2015 Pharmaceutical company Celgene has requested that the US Patent and Trademark Office sanctions hedge fund manager Kyle Bass and his company the Coalition for Affordable Drugs, arguing that the inter partes review petitions he has filed are “abusive” and a “tool to affect the stock prices of public companies”.

USPTO rejects Celgene bid for Bass sanctions

28 September 2015 The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York